Skip to content
DataLookout
Menu

NCT06100276

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 4 years 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 30, 2026 to Dec 30, 2030
    • Eligibility criteria expanded, about 12 words
    • Study completion pushed from Jun 30, 2031 to Nov 30, 2031
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 10 to 12
    • Study completion date: Mar 30, 2031 to Jun 30, 2031
    v13
  3. Minor Site details revised at 10 of 10 sitesv12
  4. Minor Site details revised at 3 of 10 sitesv11
  5. Notable Eligibility criteria expanded, about 36 words
    • Study sites: 6 to 10
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 30, 2024 to Aug 1, 2024
    • Site details revised at 6 of 6 sites
    v9
  2. Minor Study arms: 1 to 2v8
  3. Minor Study arms: 2 to 1v7
  4. Notable Enrollment target: 12 to 20v6 Show 4 more changesShow less
    • Start date: May 30, 2024 to Jul 30, 2024
    • Eligibility criteria expanded, about 9 words
    • Study sites revised (6)
    • Study arms: 1 to 2
  5. Minor Study sites: 4 to 6v5
  6. Notable Enrollment target: 42 to 12v4 Show 10 more changesShow less
    • Start date: Feb 1, 2024 to May 30, 2024
    • Eligibility criteria shortened, about 517 words
    • Primary endpoints: 3 to 1
    • Study sites: 0 to 4
    • Primary completion date: Jun 30, 2026 to Sep 30, 2026
    • Study completion date: Feb 27, 2032 to Mar 30, 2031
    • Secondary endpoints revised (2)
    • Study description revised
    • Study arms: 3 to 1
    • Study title expanded, about 1 word
  7. Notable Start date: Nov 1, 2023 to Feb 1, 2024v3
  8. Notable Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study title expanded, about 3 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To evaluate the safety and tolerability of ascending doses of intrathecally administered AMT-162 in Participants with SOD1-ALS
Timeframe: up to 5 years

Secondary (2)

Characterization of Immune Response to AMT-162 and Shedding of intrathecally administered AMT-162.
Characterization of the Effect of intrathecally administered AMT-162

Arms and interventions

3 single Ascending Dose LevelsExperimental

Experimental: 3 single Ascending Dose Levels The study will be open-label with an initial plan to explore 3 dose levels of AMT-162 in approximately 6 to 12 Participants in total. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration.

EXPANSION COHORTExperimental

Expansion cohort: To further test selected dose from the SAD part in approximately 6 to 8 participants The study will be open-label. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration.

Drugs: AMT-162

Sites

12 sites in 2 countries

United States 11, Sweden 1